PUBLISHER: The Business Research Company | PRODUCT CODE: 1730958
PUBLISHER: The Business Research Company | PRODUCT CODE: 1730958
Necrobiosis lipoidica is a rare, chronic skin condition marked by yellowish, atrophic plaques with prominent blood vessels, most often appearing on the shins. It is associated with collagen degeneration, inflammation, and lipid accumulation within the skin.
The primary treatment options for necrobiosis lipoidica (NL) include therapies, medications, and other interventions. Therapy refers to treatments aimed at alleviating or healing the condition, often incorporating medical, psychological, or physical approaches. These treatments can be administered through various routes, including oral, topical, parenteral, and other methods. The diagnosis of NL is typically made using techniques such as skin biopsy, histopathology, and other diagnostic procedures. Treatments are distributed via channels such as hospital pharmacies, online pharmacies, and retail pharmacies. Additionally, the end users of these treatments include hospitals, home care settings, specialty clinics, and other healthcare providers.
The necrobiosis lipoidica (NL) market research report is one of a series of new reports from The Business Research Company that provides necrobiosis lipoidica (NL) market statistics, including the necrobiosis lipoidica (NL) industry global market size, regional shares, competitors with the necrobiosis lipoidica (NL) market share, detailed necrobiosis lipoidica (NL) market segments, market trends, and opportunities, and any further data you may need to thrive in the necrobiosis lipoidica (NL) industry. This necrobiosis lipoidica (NL) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The necrobiosis lipoidica market size has grown strongly in recent years. It will grow from $4.08 billion in 2024 to $4.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth observed in the historical period can be attributed to factors such as the rising number of diabetes cases, the increasing prevalence of skin infections, higher healthcare spending, a growing incidence of cancer, and greater awareness of the disease.
The necrobiosis lipoidica market size is expected to see strong growth in the next few years. It will grow to $5.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The projected growth for the forecast period is driven by factors such as the increasing aging population, rising awareness of skin health and aesthetics, higher disposable incomes, growing awareness of skin health, and the rise of government initiatives. Key trends expected during this period include advancements in treatment options, improvements in diagnostic techniques, the adoption of biologics, progress in clinical trials, and the emergence of regenerative therapies.
The rising incidence of diabetes is expected to drive the growth of the necrobiosis lipoidica (NL) market in the future. Diabetes is a chronic condition where the body struggles to regulate blood sugar due to insufficient insulin production or insulin resistance, which can lead to various health complications. The increase in diabetes cases is largely attributed to sedentary lifestyles, poor diets, and genetic predisposition. Modern lifestyles, characterized by prolonged sitting, reduced physical activity, and excessive screen time, contribute to obesity and insulin resistance. High blood sugar levels in diabetes cause damage to small blood vessels (microangiopathy), which leads to poor circulation, reduced oxygen, and nutrient supply to the skin. This makes the skin more vulnerable to injury and delayed healing. As a result, skin tissue degenerates, contributing to the formation of yellowish, atrophic plaques in NL. For example, in October 2023, the National Health Service reported that the prevalence of Type 1 diabetes in England rose from 261,710 cases in 2021 to 270,935 cases in 2022, marking a 3.5% increase year-over-year. Therefore, the growing number of diabetes cases is fueling the growth of the necrobiosis lipoidica market.
The increasing incidence of autoimmune diseases is also expected to drive the growth of the necrobiosis lipoidica market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is influenced by factors such as genetic predisposition, environmental triggers, and lifestyle changes that affect immune system behavior. These diseases contribute to NL by causing chronic inflammation and immune dysfunction, which leads to collagen degeneration and impaired skin healing. For instance, in November 2024, Versorgungsatlas reported that, among 73,241,305 insured individuals in Germany, 6,304,340 were diagnosed with at least one autoimmune disease in 2022, resulting in a raw prevalence rate of 8.61%. This rising incidence of autoimmune diseases is driving the growth of the necrobiosis lipoidica market.
Leading companies in the necrobiosis lipoidica market are focusing on innovative solutions, such as developing websites for patient education, to enhance diagnosis, treatment accessibility, and disease management. Websites are digital platforms that provide information, services, or interactive features accessible via the internet. For example, in August 2022, Processa Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, launched Necrobiosislipoidicastudy.com, a website designed to raise awareness about ulcerative necrobiosis lipoidica (uNL), a rare dermatological condition. The platform provides information on the ongoing Phase 2 clinical trial evaluating PCS499 as a potential treatment for uNL, furthering the company's commitment to advancing innovative therapies for underserved patient populations.
Major players in the necrobiosis lipodica (nl) market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Bausch Health Companies Inc., Galderma Laboratories L.P., Dr. Reddy's Laboratories Ltd., Incyte Pharmaceuticals, Celltrion Healthcare Co. Ltd., Almirall S.A., Samsung Bioepis Co. Ltd., Hovione, Momenta Pharmaceuticals Inc., HanAll Biopharma Co. Ltd., Processa Pharmaceuticals.
North America was the largest region in the necrobiosis lipoidica market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in necrobiosis lipoidica (NL) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the necrobiosis lipoidica (NL) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The necrobiosis lipoidica (NL) market consists of revenues earned by entities by provide services such as dermatology consultation, wound care services, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrobiosis lipoidica market includes sales of corticosteroids, immunomodulators, corticosteroid creams, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Necrobiosis Lipodica (NL) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on necrobiosis lipodica (nl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for necrobiosis lipodica (nl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The necrobiosis lipodica (nl) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.